Q-omics provides the consensus-scored LRRC37A3 profile across patient tissues and cancer cell-line models. LRRC37A3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LRRC37A3 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, LRRC37A3 RNA expression shows 19,515 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KICH, and UVM as cancer lineages where LRRC37A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC37A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC37A3 survival associations across molecular data types. LRRC37A3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC37A3 RNA expression–survival associations across cancer types. High LRRC37A3 expression shows unfavorable associations in LUAD, KIRC, LGG and KIRP, but favorable associations in PAAD and LUSC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LRRC37A3 RNA expression.
This table summarizes LRRC37A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC37A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC37A3 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, LUAD, HNSC and BRCA. The KICH box plot shows higher LRRC37A3 RNA expression in normal versus tumor tissue (log2 FC = −1.304, t-test p < 0.001).
This table shows molecular features associated with LRRC37A3 in patient tissues and cancer cell lines. In patient samples, LRRC37A3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC37A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
